首页|论我国鼓励仿制药品目录内首仿药市场独占期制度的构建

论我国鼓励仿制药品目录内首仿药市场独占期制度的构建

扫码查看
《药品专利纠纷早期解决机制实施办法(试行)》的出台,标志着我国首仿药市场独占期制度的初步尝试,首个挑战专利成功并首个获批上市的化学仿制药给予12个月的市场独占期.但是,对鼓励仿制药品目录内品种而言,"双首"难度大,难以发挥市场独占期制度的激励功能.可以借鉴美国的制度设计,构建"专利挑战成功的首仿药"与"竞争不充分品种的首仿药"双轨并行的首仿药市场独占期制度.以首仿药市场独占期制度为主力点,配合鼓励仿制药品目录、优先审评审批制度、沟通交流机制等,形成政策合力,促进我国由仿制药大国向仿制药强国迈进.
Constructing the exclusivity system of the first generic drug of encouraged generic drug catalogs in China
The issuing of the Implementation Measures for the Mechanism for Early Settlement of Drug Patent Disputes(for Trial Implementation)marks the initial attempt of constructing the exclusivity system in China.The first chemical generic drug to successfully challenge a patent and be approved for marketing shall be granted a 12-month market exclusivity period.But it is difficult to meet the conditions of a 12-month market exclusivity period for the varieties in the Encouraged Generic Drug Catalogs.We could learn from the design of the exclusivity system in the US by building a dual-track exclusivity system,to exert the incentive function of the system.In addition,it is better to cooperate with the Encouraged Generic Drug Catalogs,the Priority Review and Approval System,the Communication Mechanism,etc.,to boost the research and development of generic drugs,as well as the quality and therapeutic effect of generic drugs.

Exclusivity systemEncouraged generic drug catalogsFirst chemical generic drug

孙旭丽、马韶青

展开 >

北京中医药大学人文学院 北京 102488

市场独占期 鼓励仿制药品目录 首仿药

北京市社科基金项目教育部社科基金项目

19GLB03218YJCZH128

2024

中国卫生法制
中国疾病预防控制中心

中国卫生法制

CHSSCD
影响因子:0.434
ISSN:1004-6607
年,卷(期):2024.32(2)
  • 24